BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 10, 2008
View Archived Issues
Recent Takeda patent reports novel proton pump inhibitors
Read More
New anticancer agents imparted in recent patent literature
Read More
New GSK-3beta inhibitors revealed in Bayer patent
Read More
BiovaxID study shows it prolongs cancer-free survival
Read More
Omrix provides interim analysis data for Fibrin Pad in mild to moderate bleeding
Read More
Evotec commences phase I trials with P2X7 antagonist
Read More
Protox presents positive 12-month data from BPH study
Read More
NIAID awards contract to IBT to develop vaccine against Ebola and Marburg viruses
Read More
Biothera completes enrollment in first arm of phase Ib/IIa trial of Imprime PGG and Erbitux
Read More
Neotropix initiates enrollment into expanded clinical trial of NTX-010 in neuroendocrine cancer
Read More
Marinus presents update on phase II clinical trials of ganaxolone in epilepsy
Read More
3M licenses TLR agonist compounds to sanofi pasteur as vaccine adjuvants
Read More
Biomarker analysis shows potential of p38 MAPK inhibitor SB-681323 in COPD
Read More
EVEREST trial: Tolvaptan beneficial in heart failure patients with renal impairment and hypotension
Read More
Similar 1-year survival seen in 3 studies of ipilimumab-treated metastatic melanoma patients
Read More
Disease stabilization seen with vatalanib in metastatic melanoma patients
Read More
Biofrontera completes treatment and evaluation in phase III BF-200 ALA trial
Read More
Phase I trial of Inspire's INS-117548 for glaucoma begins
Read More
QLT initiates phase I trial of synthetic retinoid product QLT-091001
Read More
NCCN, Abraxis and AstraZeneca enter collaboration to conduct studies of Abraxane
Read More
Invitrogen notifies European Commission of pending merger with Applied Biosystems
Read More
Icagen initiates phase II proof-of-concept trial for senicapoc in allergic asthma
Read More
R&D highlights from the UBS Global Life Sciences Conference in New York: Santhera Pharmaceuticals
Read More
Santhera launches Catena in Canada for Friedreich's ataxia
Read More
Shionogi's acquisition of Sciele complete
Read More
DeveloGen completes phase I trial of somatostatin analogue DG-3173 for acromegaly
Read More
Circassia acquires North American and Japanese rights to dopexamine from Ipsen
Read More
P144 TGF-beta1 inhibitor safe in phase I study in healthy volunteers
Read More
